Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice

Giovanni Corrao, Federica Nicotra, Andrea Parodi, Antonella Zambon, Franca Heiman, Luca Merlino, Ida Fortino, Giancarlo Cesana, Giuseppe Mancia

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Guidelines recommend a combination of 2 drugs to be used as first-step treatment strategy in high-risk hypertensive individuals to achieve timely blood pressure control and avoid early events. The evidence that this is associated with cardiovascular (CV) benefits compared with initial monotherapy is limited, however. The objective of this study was to assess whether, compared with antihypertensive monotherapy, a combination of antihypertensive drugs provides a greater CV protection in daily clinical practice. A population-based, nested case-control study was carried out by including the cohort of 209 650 patients from Lombardy (Italy) aged 40 to 79 years who were newly treated with antihypertensive drugs between 2000 and 2001. Cases were the 10 688 patients who experienced a hospitalization for CV disease from initial prescription until 2007. Three controls were randomly selected for each case. Logistic regression was used to model the CV risk associated with starting on and/or continuing with combination therapy. A Monte-Carlo sensitivity analysis was performed to account for unmeasured confounders. Patients starting on combination therapy had an 11% CV risk reduction with respect to those starting on monotherapy (95% CI: 5% to 16%). Compared with patients who maintained monotherapy also during follow-up, those who started on combination therapy and kept it along the entire period of observation had 26% reduction of CV risk (95% CI: 15% to 35%). In daily life practice, a combination of antihypertensive drugs is associated with a great reduction of CV risk. The indication for using combination of blood pressure drugs should be broadened.

Original languageEnglish
Pages (from-to)566-572
Number of pages7
JournalHypertension
Volume58
Issue number4
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Antihypertensive Agents
Risk Reduction Behavior
Cardiovascular Models
Blood Pressure
Drug Combinations
Therapeutics
Italy
Prescriptions
Case-Control Studies
Hospitalization
Cardiovascular Diseases
Logistic Models
Observation
Guidelines
Pharmaceutical Preparations
Population

Keywords

  • blood pressure-lowering agents
  • cardiovascular outcomes
  • combination therapy
  • monotherapy
  • record linkage

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Corrao, G., Nicotra, F., Parodi, A., Zambon, A., Heiman, F., Merlino, L., ... Mancia, G. (2011). Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension, 58(4), 566-572. https://doi.org/10.1161/HYPERTENSIONAHA.111.177592

Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. / Corrao, Giovanni; Nicotra, Federica; Parodi, Andrea; Zambon, Antonella; Heiman, Franca; Merlino, Luca; Fortino, Ida; Cesana, Giancarlo; Mancia, Giuseppe.

In: Hypertension, Vol. 58, No. 4, 10.2011, p. 566-572.

Research output: Contribution to journalArticle

Corrao, G, Nicotra, F, Parodi, A, Zambon, A, Heiman, F, Merlino, L, Fortino, I, Cesana, G & Mancia, G 2011, 'Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice', Hypertension, vol. 58, no. 4, pp. 566-572. https://doi.org/10.1161/HYPERTENSIONAHA.111.177592
Corrao, Giovanni ; Nicotra, Federica ; Parodi, Andrea ; Zambon, Antonella ; Heiman, Franca ; Merlino, Luca ; Fortino, Ida ; Cesana, Giancarlo ; Mancia, Giuseppe. / Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. In: Hypertension. 2011 ; Vol. 58, No. 4. pp. 566-572.
@article{3658ba1361924667bf7c50d9c726e1f0,
title = "Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice",
abstract = "Guidelines recommend a combination of 2 drugs to be used as first-step treatment strategy in high-risk hypertensive individuals to achieve timely blood pressure control and avoid early events. The evidence that this is associated with cardiovascular (CV) benefits compared with initial monotherapy is limited, however. The objective of this study was to assess whether, compared with antihypertensive monotherapy, a combination of antihypertensive drugs provides a greater CV protection in daily clinical practice. A population-based, nested case-control study was carried out by including the cohort of 209 650 patients from Lombardy (Italy) aged 40 to 79 years who were newly treated with antihypertensive drugs between 2000 and 2001. Cases were the 10 688 patients who experienced a hospitalization for CV disease from initial prescription until 2007. Three controls were randomly selected for each case. Logistic regression was used to model the CV risk associated with starting on and/or continuing with combination therapy. A Monte-Carlo sensitivity analysis was performed to account for unmeasured confounders. Patients starting on combination therapy had an 11{\%} CV risk reduction with respect to those starting on monotherapy (95{\%} CI: 5{\%} to 16{\%}). Compared with patients who maintained monotherapy also during follow-up, those who started on combination therapy and kept it along the entire period of observation had 26{\%} reduction of CV risk (95{\%} CI: 15{\%} to 35{\%}). In daily life practice, a combination of antihypertensive drugs is associated with a great reduction of CV risk. The indication for using combination of blood pressure drugs should be broadened.",
keywords = "blood pressure-lowering agents, cardiovascular outcomes, combination therapy, monotherapy, record linkage",
author = "Giovanni Corrao and Federica Nicotra and Andrea Parodi and Antonella Zambon and Franca Heiman and Luca Merlino and Ida Fortino and Giancarlo Cesana and Giuseppe Mancia",
year = "2011",
month = "10",
doi = "10.1161/HYPERTENSIONAHA.111.177592",
language = "English",
volume = "58",
pages = "566--572",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice

AU - Corrao, Giovanni

AU - Nicotra, Federica

AU - Parodi, Andrea

AU - Zambon, Antonella

AU - Heiman, Franca

AU - Merlino, Luca

AU - Fortino, Ida

AU - Cesana, Giancarlo

AU - Mancia, Giuseppe

PY - 2011/10

Y1 - 2011/10

N2 - Guidelines recommend a combination of 2 drugs to be used as first-step treatment strategy in high-risk hypertensive individuals to achieve timely blood pressure control and avoid early events. The evidence that this is associated with cardiovascular (CV) benefits compared with initial monotherapy is limited, however. The objective of this study was to assess whether, compared with antihypertensive monotherapy, a combination of antihypertensive drugs provides a greater CV protection in daily clinical practice. A population-based, nested case-control study was carried out by including the cohort of 209 650 patients from Lombardy (Italy) aged 40 to 79 years who were newly treated with antihypertensive drugs between 2000 and 2001. Cases were the 10 688 patients who experienced a hospitalization for CV disease from initial prescription until 2007. Three controls were randomly selected for each case. Logistic regression was used to model the CV risk associated with starting on and/or continuing with combination therapy. A Monte-Carlo sensitivity analysis was performed to account for unmeasured confounders. Patients starting on combination therapy had an 11% CV risk reduction with respect to those starting on monotherapy (95% CI: 5% to 16%). Compared with patients who maintained monotherapy also during follow-up, those who started on combination therapy and kept it along the entire period of observation had 26% reduction of CV risk (95% CI: 15% to 35%). In daily life practice, a combination of antihypertensive drugs is associated with a great reduction of CV risk. The indication for using combination of blood pressure drugs should be broadened.

AB - Guidelines recommend a combination of 2 drugs to be used as first-step treatment strategy in high-risk hypertensive individuals to achieve timely blood pressure control and avoid early events. The evidence that this is associated with cardiovascular (CV) benefits compared with initial monotherapy is limited, however. The objective of this study was to assess whether, compared with antihypertensive monotherapy, a combination of antihypertensive drugs provides a greater CV protection in daily clinical practice. A population-based, nested case-control study was carried out by including the cohort of 209 650 patients from Lombardy (Italy) aged 40 to 79 years who were newly treated with antihypertensive drugs between 2000 and 2001. Cases were the 10 688 patients who experienced a hospitalization for CV disease from initial prescription until 2007. Three controls were randomly selected for each case. Logistic regression was used to model the CV risk associated with starting on and/or continuing with combination therapy. A Monte-Carlo sensitivity analysis was performed to account for unmeasured confounders. Patients starting on combination therapy had an 11% CV risk reduction with respect to those starting on monotherapy (95% CI: 5% to 16%). Compared with patients who maintained monotherapy also during follow-up, those who started on combination therapy and kept it along the entire period of observation had 26% reduction of CV risk (95% CI: 15% to 35%). In daily life practice, a combination of antihypertensive drugs is associated with a great reduction of CV risk. The indication for using combination of blood pressure drugs should be broadened.

KW - blood pressure-lowering agents

KW - cardiovascular outcomes

KW - combination therapy

KW - monotherapy

KW - record linkage

UR - http://www.scopus.com/inward/record.url?scp=80053562658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053562658&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.111.177592

DO - 10.1161/HYPERTENSIONAHA.111.177592

M3 - Article

C2 - 21825231

AN - SCOPUS:80053562658

VL - 58

SP - 566

EP - 572

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 4

ER -